DOSE OF REALITY: BIG PHARMA’S EGREGIOUS GLP-1 WEIGHT LOSS DRUG PRICES COULD COST MEDICARE $35 BILLION
Oct 10, 2024
CBO Confirms Cost of Blockbuster Obesity Drugs at Current Prices Would… Read More
© 2024 CSRXP- All Rights Reserved
Dose of Reality
DOSE OF REALITY: BRAND NAME DRUG MAKERS INCREASINGLY UTILIZING ‘USE CODES’ TO GAME PATENT SYSTEM AND BLOCK COMPETITION
Sep 30, 2024
STAT Analysis Finds Drug Makers Gaming FDA Orange Book Process to Further… Read More
DOSE OF REALITY: BIG PHARMA’S GLP-1 PRICE-GOUGING UNSUSTAINABLE FOR AMERICAN PATIENTS AND THE U.S. HEALTH SYSTEM
Sep 23, 2024
Brand Name Drug Companies Applying Price-Hiking, Patent Abuse Playbook to… Read More
DOSE OF REALITY: BIG PHARMA SETS DRUG PRICES, HIKES DRUG PRICES AND BLOCKS COMPETITION TO KEEP DRUG PRICES HIGH
Sep 10, 2024
Lawmakers Should Focus on Holding Big Pharma Accountable for Egregious Pricing… Read More
DOSE OF REALITY: BIG PHARMA’S EGREGIOUS GLP-1, GENE, AND CELL THERAPY PRICES PROJECTED TO INCREASE HEALTH CARE COSTS FOR EMPLOYERS
Aug 26, 2024
Analysis Finds GLP-1 Blockbusters and “Multimillion-Dollar Gene Therapies”… Read More
DOSE OF REALITY: FORBES: HOW BIG PHARMA EXPLOITS LOOPHOLES IN THE PATENT SYSTEM
Jun 25, 2024
Avik Roy Highlights How Increased USPTO-FDA Collaboration and Greater Scrutiny… Read More
DOSE OF REALITY: FORBES: MAKING IT HARDER TO CHALLENGE BIG PHARMA’S PATENT THICKETS WOULD RAISE DRUG PRICES, UNDERMINE TRUE INNOVATION
Jun 5, 2024
Research Article Explores Negative Implications of Proposal to Restrict Key… Read More
DOSE OF REALITY: FORBES: HOW BIG PHARMA STIFLES COMPETITION WITH PRODUCT SHOPPING
May 23, 2024
Research Column Explores Case Study in Common Patent Abuse Tactic That… Read More
DOSE OF REALITY: BIG PHARMA’S PATENT ABUSE BLOCKS COMPETITION IN THE PRESCRIPTION DRUG MARKET, KEEPS DRUG PRICES HIGH
May 21, 2024
Senate Hearing Offers Opportunity to Highlight Market-Based Solutions to Hold… Read More
DOSE OF REALITY: STUDY FINDS NEARLY THREE-QUARTERS OF BIG PHARMA’S PATENTS ON TOP-SELLING DRUGS FILED AFTER FDA APPROVAL
May 16, 2024
Analysis Showcases Egregious Scale of Big Pharma’s Patent Thickets on… Read More
DOSE OF REALITY: IQVIA REPORT SHOWS HOW BIG PHARMA’S EGREGIOUS PRICING PRACTICES DRIVE INCREASED PRESCRIPTION DRUG SPENDING
May 10, 2024
Analysis Shows Price Hikes Outpacing Inflation, Rising Launch Prices and… Read More
DOSE OF REALITY: BIOSIMILAR COMPETITION GENERATES SIGNIFICANT SAVINGS FOR PATIENTS AND THE U.S. HEALTH CARE SYSTEM
May 2, 2024
Reports Find Biosimilars Have Lower Prices Than Brand Name Biologics… Read More